Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, botulinum toxin type A (Botox®) cannot be endorsed for use within NHS Wales for the treatment of focal lower limb spasticity, including the treatment of ankle disability due to lower limb spasticity associated with stroke in adults. |
||
|
||
Medicine details |
||
| Medicine name | botulinum toxin A (Botox®) | |
| Formulation | Not known | |
| Reference number | 2540 | |
| Indication | Treatment of focal lower limb spasticity, including the treatment of ankle disability due to lower limb spasticity associated with stroke in adults |
|
| Company | Allergan Ltd | |
| BNF chapter | Central nervous system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 24/09/2014 | |